¾«¶«´«Ã½

SEATTLE, WA, July 16, 2026 — ¾«¶«´«Ã½, Inc., a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) recently cleared its Investigational New Drug (IND) application for UB-VV400, a CD22-directed in vivo ¾«¶«´«Ã½ T cell therapy candidate for […]

– Industry’s First Combination BCMA x GPRC5D In Vivo ¾«¶«´«Ã½ T Cell Therapy for the Treatment of Multiple Myeloma – SEATTLE, WA, April 27, 2026 — ¾«¶«´«Ã½, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, today announced the acceptance of a

SEATTLE, WA, March 23, 2026 — ¾«¶«´«Ã½, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, today announced the appointment of Marcela Maus, M.D., Ph.D., and Athena Countouriotis, M.D., to its Board of Directors. Drs. Maus and Countouriotis bring deep expertise spanning

SEATTLE, WA, September 30, 2025 — ¾«¶«´«Ã½, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of ¾«¶«´«Ã½ T cells, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to UB-VV111 for the treatment of relapsed/refractory Large B-cell Lymphoma following

SEATTLE, WA, September 23, 2025 – ¾«¶«´«Ã½, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of ¾«¶«´«Ã½ T cells, today announced its recognition by both Endpoints News and Fierce Biotech as one of the most promising biotechnology companies of the year. Umoja is honored to be named